PETACH TIKVA, Israel,
April 20, 2016 /PRNewswire/ --
Macrocure Ltd. (NASDAQ: MCUR) ("Macrocure" or the
"Company"), a clinical-stage biotechnology company,
announced today that it has filed its annual report on Form 20-F
for the fiscal year ended December 31,
2015 with the U.S. Securities and Exchange Commission (the
"SEC"). The annual report on Form 20-F, which contains
Macrocure's audited financial statements, can be accessed on the
SEC's website at http://www.sec.gov, as well as via the Company's
investor relations website at
http://investor.macrocure.com/annuals-proxies.cfm. The Company will
deliver a hard copy of its annual report on Form 20-F, including
its complete audited financial statements, free of charge, to its
shareholders upon request to Shai
Lankry, the Company's Chief Financial Officer, at
+972-3-923-5556, or Shai@Macrocure.com.
About Macrocure Ltd.
Macrocure Ltd. is a clinical-stage biotechnology company that
until recently was focused on developing a novel therapeutic
platform to address chronic and hard-to-heal wounds. For more
information, please visit http://www.Macrocure.com.
For Investors:
Shai Lankry
Macrocure Ltd.
Shai@macrocure.com
+972-3-7631409
SOURCE Macrocure Ltd.
